Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Testing monotherapy and combination therapy in one trial with biomarker consideration.

Sun LZ, Kang SP, Chen C.

Contemp Clin Trials. 2019 Jul;82:53-59. doi: 10.1016/j.cct.2019.06.002. Epub 2019 Jun 12.

PMID:
31201949
2.

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Wang M, Chen C, Jemielita T, Anderson J, Li XN, Hu C, Kang SP, Ibrahim N, Ebbinghaus S.

J Immunother Cancer. 2019 Feb 8;7(1):39. doi: 10.1186/s40425-019-0513-4.

3.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.

Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K.

JAMA Oncol. 2019 Apr 1;5(4):546-550. doi: 10.1001/jamaoncol.2018.5441.

PMID:
30570649
4.

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Dec 1;24(23):6098. doi: 10.1158/1078-0432.CCR-18-3340. No abstract available.

PMID:
30510087
5.

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.

Kang SP, Gergich K, Lubiniecki GM, de Alwis DP, Chen C, Tice MAB, Rubin EH.

Ann Oncol. 2017 Jun 1;28(6):1388-1398. doi: 10.1093/annonc/mdx076. No abstract available.

6.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators.

Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.

PMID:
29880231
7.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Oct 15;24(20):4960-4967. doi: 10.1158/1078-0432.CCR-17-2386. Epub 2018 Apr 23. Erratum in: Clin Cancer Res. 2018 Dec 1;24(23):6098.

8.

The spin structures of interlayer coupled magnetic films with opposite chirality.

Kang SP, Kim NJ, Kwon HY, Choi JW, Min BC, Won C.

Sci Rep. 2018 Feb 5;8(1):2361. doi: 10.1038/s41598-018-20800-8.

9.

A Blueprint to Advance Colorectal Cancer Immunotherapies.

Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB.

Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16.

10.

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK.

J Clin Invest. 2017 Aug 1;127(8):2930-2940. doi: 10.1172/JCI91190. Epub 2017 Jun 26.

11.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

12.

Out-of-plane chiral domain wall spin-structures in ultrathin in-plane magnets.

Chen G, Kang SP, Ophus C, N'Diaye AT, Kwon HY, Qiu RT, Won C, Liu K, Wu Y, Schmid AK.

Nat Commun. 2017 May 19;8:15302. doi: 10.1038/ncomms15302.

13.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O.

J Clin Oncol. 2016 Dec;34(34):4102-4109. Epub 2016 Oct 31.

14.

Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial.

Elassaiss-Schaap J, Rossenu S, Lindauer A, Kang SP, de Greef R, Sachs JR, de Alwis DP.

CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):21-28. doi: 10.1002/psp4.12132. Epub 2016 Nov 8.

15.

miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2).

Cao CL, Niu HJ, Kang SP, Cong CL, Kang SR.

Eur Rev Med Pharmacol Sci. 2016 Sep;20(17):3574-81.

16.

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A.

Eur J Cancer. 2016 Nov;67:46-54. doi: 10.1016/j.ejca.2016.07.018. Epub 2016 Sep 2.

17.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830
18.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD.

J Clin Oncol. 2016 May 1;34(13):1510-7. doi: 10.1200/JCO.2015.64.0391. Epub 2016 Mar 7.

19.

Antiferromagnetic proximity effect in epitaxial CoO/NiO/MgO(001) systems.

Li Q, Liang JH, Luo YM, Ding Z, Gu T, Hu Z, Hua CY, Lin HJ, Pi TW, Kang SP, Won C, Wu YZ.

Sci Rep. 2016 Mar 2;6:22355. doi: 10.1038/srep22355.

20.

Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.

Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP.

Clin Cancer Res. 2016 Mar 15;22(6):1318-24. doi: 10.1158/1078-0432.CCR-15-1295. Epub 2015 Nov 23. Review.

21.

Pembrolizumab.

Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM.

J Immunother Cancer. 2015 Aug 18;3:36. doi: 10.1186/s40425-015-0078-9. eCollection 2015. Review.

22.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.

Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.

PMID:
26115796
23.

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW.

Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.

24.

Unlocking Bloch-type chirality in ultrathin magnets through uniaxial strain.

Chen G, N'Diaye AT, Kang SP, Kwon HY, Won C, Wu Y, Qiu ZQ, Schmid AK.

Nat Commun. 2015 Mar 23;6:6598. doi: 10.1038/ncomms7598.

PMID:
25798953
25.

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN.

J Clin Oncol. 2015 Mar 20;33(9):1060-6. doi: 10.1200/JCO.2014.57.5027. Epub 2015 Jan 20.

PMID:
25605849
26.

Postoperative hypocaloric peripheral parenteral nutrition with branched-chain-enriched amino acids provides no better clinical advantage than fluid management in nonmalnourished colorectal cancer patients.

Huang HH, Wu PC, Kang SP, Wang JH, Hsu CW, Chwang LC, Chang SJ.

Nutr Cancer. 2014;66(8):1269-78. doi: 10.1080/01635581.2014.956248. Epub 2014 Oct 8.

PMID:
25298128
27.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A.

Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.

PMID:
25034862
28.

First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.

Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ.

Clin Cancer Res. 2014 Apr 15;20(8):2205-14. doi: 10.1158/1078-0432.CCR-13-1880. Epub 2014 Feb 21.

29.

Glycyrrhetinic acid suppressed NF-κB activation in TNF-α-induced hepatocytes.

Chen HJ, Kang SP, Lee IJ, Lin YL.

J Agric Food Chem. 2014 Jan 22;62(3):618-25. doi: 10.1021/jf405352g. Epub 2014 Jan 10.

PMID:
24386942
30.

Catastrophic growth of gas hydrates in the presence of kinetic hydrate inhibitors.

Cha M, Shin K, Seo Y, Shin JY, Kang SP.

J Phys Chem A. 2013 Dec 27;117(51):13988-95. doi: 10.1021/jp408346z. Epub 2013 Dec 11.

PMID:
24295438
31.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A.

N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

32.

Ultrasound-guided transcervical forceps extraction of unruptured interstitial pregnancy.

Ahn JW, Lee SJ, Lee SH, Kang SP, Won HS.

BJOG. 2013 Sep;120(10):1285-8. doi: 10.1111/1471-0528.12265. Epub 2013 May 20.

33.

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.

Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE.

Clin Cancer Res. 2013 Jun 1;19(11):3059-67. doi: 10.1158/1078-0432.CCR-12-3829. Epub 2013 Apr 3.

34.

Estimation of renal cell carcinoma treatment effects from disease progression modeling.

Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR.

Clin Pharmacol Ther. 2013 Apr;93(4):345-51. doi: 10.1038/clpt.2012.263. Epub 2012 Dec 27.

35.

Severity of illness influences the efficacy of enteral feeding route on clinical outcomes in patients with critical illness.

Huang HH, Chang SJ, Hsu CW, Chang TM, Kang SP, Liu MY.

J Acad Nutr Diet. 2012 Aug;112(8):1138-46. doi: 10.1016/j.jand.2012.04.013. Epub 2012 Jun 7.

PMID:
22682883
36.

Association between illness severity and timing of initial enteral feeding in critically ill patients: a retrospective observational study.

Huang HH, Hsu CW, Kang SP, Liu MY, Chang SJ.

Nutr J. 2012 May 3;11:30. doi: 10.1186/1475-2891-11-30.

37.

Spectroscopic identification on cage occupancies of binary gas hydrates in the presence of ethanol.

Lee JW, Kang SP.

J Phys Chem B. 2012 Jan 12;116(1):332-5. doi: 10.1021/jp210223r. Epub 2011 Dec 14.

PMID:
22168376
38.

Tuning ionic liquids for hydrate inhibition.

Kim KS, Kang JW, Kang SP.

Chem Commun (Camb). 2011 Jun 14;47(22):6341-3. doi: 10.1039/c0cc05676f. Epub 2011 May 6.

PMID:
21547283
40.

Three-drug combination regimen in pancreatic cancer treatment: are we there yet?

Kang SP, Saif MW.

JOP. 2011 Mar 9;12(2):78-82. No abstract available.

41.

Effect of levothyroxine treatment on in vitro fertilization and pregnancy outcome in infertile women with subclinical hypothyroidism undergoing in vitro fertilization/intracytoplasmic sperm injection.

Kim CH, Ahn JW, Kang SP, Kim SH, Chae HD, Kang BM.

Fertil Steril. 2011 Apr;95(5):1650-4. doi: 10.1016/j.fertnstert.2010.12.004. Epub 2010 Dec 30.

PMID:
21193190
42.

Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.

Kang SP, Ratain MJ.

Clin Cancer Res. 2010 Sep 1;16(17):4446-51. doi: 10.1158/1078-0432.CCR-10-0663. Epub 2010 Aug 24.

43.

A pharmacogenetic study of vorinostat glucuronidation.

Kang SP, Ramirez J, House L, Zhang W, Mirkov S, Liu W, Haverfield E, Ratain MJ.

Pharmacogenet Genomics. 2010 Oct;20(10):638-41. doi: 10.1097/FPC.0b013e32833e1b37.

45.

Formation characteristics of synthesized natural gas hydrates in meso- and macroporous silica gels.

Kang SP, Lee JW.

J Phys Chem B. 2010 May 27;114(20):6973-8. doi: 10.1021/jp100812p.

PMID:
20429536
46.

Inhibition of natural gas hydrates in the presence of liquid hydrocarbons forming structure H.

Seo Y, Kang SP, Jang W, Kim S.

J Phys Chem B. 2010 May 13;114(18):6084-8. doi: 10.1021/jp910941d.

PMID:
20397674
47.

Structure and composition analysis of natural gas hydrates: 13C NMR spectroscopic and gas uptake measurements of mixed gas hydrates.

Seo Y, Kang SP, Jang W.

J Phys Chem A. 2009 Sep 3;113(35):9641-9. doi: 10.1021/jp904994s.

PMID:
19658414
48.

Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.

Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN.

Int J Biol Markers. 2009 Jan-Mar;24(1):1-10.

PMID:
19404916
49.

Duodenal versus gastric feeding in medical intensive care unit patients: a prospective, randomized, clinical study.

Hsu CW, Sun SF, Lin SL, Kang SP, Chu KA, Lin CH, Huang HH.

Crit Care Med. 2009 Jun;37(6):1866-72. doi: 10.1097/CCM.0b013e31819ffcda.

PMID:
19384225
50.

Global variation in CYP2C8-CYP2C9 functional haplotypes.

Speed WC, Kang SP, Tuck DP, Harris LN, Kidd KK.

Pharmacogenomics J. 2009 Aug;9(4):283-90. doi: 10.1038/tpj.2009.10. Epub 2009 Apr 21.

Supplemental Content

Support Center